<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39428656</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-8978</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Long term mortality trends in people with severe mental illnesses and how COVID-19, ethnicity and other chronic mental health comorbidities contributed: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>11</EndPage><MedlinePgn>1-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0033291724001843</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">People with schizophrenia-spectrum and bipolar disorders (severe mental illnesses; 'SMI') experience excess mortality. Our aim was to explore longer-term trends in mortality, including the COVID-19 pandemic period, with a focus on additional vulnerabilities (psychiatric comorbidities and race/ ethnicity) in SMI.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective cohort study using electronic health records from secondary mental healthcare, covering a UK region of 1.3 million people. Mortality trends spanning fourteen years, including the COVID-19 pandemic, were assessed in adults with clinician-ascribed ICD-10 diagnoses for schizophrenia-spectrum and bipolar disorders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The sample comprised 22 361 people with SMI with median follow-up of 10.6 years. Standardized mortality ratios were more than double the population average pre-pandemic, increasing further during the pandemic, particularly in those with SMI and psychiatric comorbidities. Mortality risk increased steadily among people with SMI and comorbid depression, dementia, substance use disorders and anxiety over 13-years, increasing further during the pandemic. COVID-19 mortality was elevated in people with SMI and comorbid depression (sub-Hazard Ratio: 1.48 [95% CI 1.03-2.13]), dementia (sHR:1.96, 1.26-3.04) and learning disabilities (sHR:2.30, 1.30-4.06), compared to people with only SMI. COVID-19 mortality risk was similar for minority ethnic groups and White British people with SMI. Elevated all-cause mortality was evident in Black Caribbean (adjusted Rate Ratio: 1.40, 1.11-1.77) and Black African people with SMI (aRR: 1.59, 1.07-2.37) during the pandemic relative to earlier years.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mortality has increased over time in people with SMI. The pandemic exacerbated pre-existing trends. Actionable solutions are needed which address wider social determinants and address disease silos.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Das-Munshi</LastName><ForeName>Jayati</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3913-6859</Identifier><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neurosciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ESRC Centre for Society and Mental Health, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South London &amp; Maudsley NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Improvement UK (PHI-UK), UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakolis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre for Implementation Science, Health Service &amp; Population Research Department, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>BÃ©cares</LastName><ForeName>Laia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Global Health &amp; Social Medicine, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dasch</LastName><ForeName>Hannah K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neurosciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dyer</LastName><ForeName>Jacqui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NHS England &amp; NHS Improvement (NHS-E/I), Black Thrive Global, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotopf</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neurosciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South London &amp; Maudsley NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Improvement UK (PHI-UK), UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildersley</LastName><ForeName>Rosie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neurosciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ESRC Centre for Society and Mental Health, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ocloo</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Implementation Science, Health Service &amp; Population Research Department, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Research (NIHR) Applied Research Collaboration (ARC) South London, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, De Crespigny Park, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neurosciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South London &amp; Maudsley NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuart</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Implementation Science, Health Service &amp; Population Research Department, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dregan</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neurosciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Improvement UK (PHI-UK), UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">bipolar affective disorders</Keyword><Keyword MajorTopicYN="N">comorbidities</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">race/ethnicity</Keyword><Keyword MajorTopicYN="N">schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>1</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39428656</ArticleId><ArticleId IdType="doi">10.1017/S0033291724001843</ArticleId><ArticleId IdType="pii">S0033291724001843</ArticleId></ArticleIdList></PubmedData></PubmedArticle>